COMMUNIQUÉS West-GlobeNewswire

Nephros Announces Listing on Nasdaq Capital Market
13/08/2019
SOUTH ORANGE, NJ, Aug. 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (OTCQB: NEPH), a commercial-stage company that develops and sells high performance water purification products to the medical device [...]
ProMIS Neurosciences Announces Second Quarter 2019 Results
13/08/2019
Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer’s, ALS and Parkinson’s disease TORONTO and CAMBRIDGE, Mass., Aug. 13, 2019 (GLOBE NEWSWIRE) -- ProMIS [...]
VBL Therapeutics Announces Second Quarter 2019 Financial Results
13/08/2019
Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel, Aug. 13, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the second quarter ended June 30, 2019, [...]
Sol-Gel Technologies Reports Second Quarter 2019 Financial Results and Corporate Update
13/08/2019
Top-line generic product revenue of $7.8 million TWIN Phase 3 trials are fully enrolled and remain on track to report results in 4Q19 NESS ZIONA, Israel, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. ( [...]
CureVac Enters into an Exclusive Collaborative Research Agreement for Discovery Research in mRNA-based Lung Therapy Candidates with Yale University
13/08/2019
TÜBINGEN, Germany and BOSTON, Aug. 13, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today it has entered into a Collaborative [...]
Pulmocide announces Journal of Antimicrobial Chemotherapy publication of novel antifungal PC945 activity against Candida auris, a health threat gaining global prominence
13/08/2019
Pulmocide announces Journal of Antimicrobial Chemotherapy publication of novel antifungal PC945 activity against Candida auris, a health threat gaining global prominence C.auris is often multi-drug resistant and new [...]
Trillium Therapeutics Reports Second Quarter 2019 Financial Results
13/08/2019
TORONTO, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial [...]
Covetrus Announces Financial Results for Second Quarter of 2019
13/08/2019
Net sales of $1,009 million, relatively flat year-over-year, non-GAAP pro forma organic net sales declined 1% year-over-year In North America, net sales of $552 million, or a 6% increase year-over-year; prescription [...]
AzurRx BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
13/08/2019
On track to report top line data in Phase II OPTION Study in September 2019 NEW YORK, Aug. 13, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“AzurRx” or the “Company”), a company specializing in the [...]
MediWound Reports Second Quarter 2019 Financial Results
13/08/2019
Total revenues of $20.7 million, driven primarily by the upfront payment from Vericel for NexoBrid ® license agreement BARDA committed additional $21 million to fund NexoBrid ® expanded access treatment protocol [...]
ASLAN Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
13/08/2019
SINGAPORE, Aug. 13, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for the quarter ended 30 [...]
Six-month interim report (Q2) 2019
13/08/2019
Upgraded financial outlook and on track to deliver double-digit growth (unaudited) In Q2, ALK continued to deliver on its strategy, with broad-based growth across all regions and further strong performance from tablets [...]
Basilea starts phase 1/2 study with derazantinib in urothelial cancer
13/08/2019
Basel, Switzerland, August 13, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has initiated the phase 1/2 FIDES-02 study with the pan-fibroblast growth factor receptor (FGFR) kinase inhibitor [...]
Emerald Health Therapeutics’ Pure Sunfarms JV Reaches Q2 Sales of $32 Million, 78% EBITDA Margin, $0.65/Gram All-in Production Cost, and Third Consecutive Quarter of Profitability
13/08/2019
Emerald Health Therapeutics to report second quarter 2019 financial results on August 28th and hold conference call August 29th VICTORIA, British Columbia, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, [...]
Adamas Announces New Employment Inducement Grant
12/08/2019
EMERYVILLE, Calif., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the [...]
MediPharm Labs Reports Strong, Profitable Second Quarter Results
12/08/2019
Q2 2019 Revenue of $31.5 Million, Adjusted EBITDA of $7.7 Million, Net Income before tax of $4.1 Million TORONTO, Aug. 12, 2019 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm [...]
Novelion Therapeutics Announces Anticipated Late Filing of Quarterly Report on Form 10-Q for the Quarter Ended June 30, 2019
12/08/2019
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals [...]
Molecular Templates, Inc. Reports Second Quarter 2019 Financial Results
12/08/2019
AUSTIN, Texas, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular,” “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and [...]
Equillium Reports Second Quarter 2019 Financial Results and Recent Highlights
12/08/2019
Initiated Phase 1b EQUIP proof-of-concept trial evaluating itolizumab (EQ001) for the treatment of uncontrolled asthma Investigational New Drug (IND) application accepted by FDA for itolizumab for the treatment of lupus [...]

Pages